Response to comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.

Cancer Letters

Volumn 231, Issue 1, 2006, Pages 146-148

  El Zein, Randa A ^a   Hay, Matthew J ^b   Lopez, Mirtha S ^a   Bondy, Melissa L ^a   Morris, Debra L ^b   Legator, Marvin S ^b   Abdel Rahman, Sherif Z ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CLASTOGEN; METHYLPHENIDATE; PYRIDINE; TETRACHLOROETHYLENE; TETRAHYDROFURAN;

ATTENTION DEFICIT DISORDER; BIOASSAY; BLOOD CULTURE; BLOOD SAMPLING; CANCER; CANCER RISK; CARCINOGENICITY; CHROMOSOME DAMAGE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DIET; DRUG SAFETY; DRUG SCREENING; FEMALE; FOLLOW UP; GENETIC DAMAGE; GENOTOXICITY; HEPATOBLASTOMA; HUMAN; LETTER; LIFESTYLE; LITERATURE; LIVER CELL CARCINOMA; MALE; MEDICAL RECORD; MOUSE; NONHUMAN; PEDIATRICIAN; PRIORITY JOURNAL; PUBLICATION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARCINOGENS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHROMOSOME ABERRATIONS; DNA DAMAGE; ENDPOINT DETERMINATION; HUMANS; METHYLPHENIDATE; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK FACTORS;

EID: 28844489521     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.007     Document Type: Letter

References (11)

1. R.A. El-Zein, S.Z. Abdel-Rahman, M.J. Hay, M.S. Lopez, M.L. Bondy, D.L. Morris, and M.S. Legator Cytogenetic effects in children treated with methylphenidate Cancer Lett. 230 2005 1 8
2. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Methylphenidate, March 2005, Available at http://cerhr.niehs.nih. gov/news/stimulants/reports.html
3. J.V. Selby, G.D. Friedman, and B.H. Fireman Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up Cancer Res. 49 1989 5736 5747
4. NTP-long-term study reports and abstracts, available at http://ntp.niehs.nih.gov.
5. L. Hagmar, S. Bonassi, U. Stromberg, A. Brøgger, L. Knudsen, H. Norppa, and C. Reuterwall Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH) Cancer Res. 58 1998 4117 4121
6. S.H. Liou, J.C. Lung, Y.H. Chen, T. Yang, L.L. Hsieh, C.J. Chen, and T.N. Wu Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area Cancer Res. 59 1999 1481 1484
7. S. Bonassi, L. Hagmar, U. Stromberg, A. Huici Montagud, H. Tinnerberg, A. Forni, and for the European Study Group on Cytogenetic Biomarkers and Health (ESCH) Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens Cancer Res. 60 2000 1619 1625
8. Z. Smerhovsky, K. Landa, P. Rossner, M. Brabec, Z. Zudova, and N. Hola Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations Environ. Health Perspect. 109 2001 41 45
9. P. Rossner, P. Boffetta, M. Ceppi, S. Bonassi, Z. Smerhovsky, and K. Landa Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer Environ. Health Perspect. 113 2005 517 520
10. S. Bonassi, A. Znaor, H. Norppa, and L. Hagmar Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective Cytogenet. Genome Res. 104 2004 376 382
11. S. Bonassi, D. Uggolini, M. Kirsch-Volders, U. Stromberg, R. Vermeulen, and J. Tucker Human population studies with cytogenetic biomarkers: Review of the literature and future prospectives Environ. Mol. Mutagen. 45 2005 258 270